Finoriq research workspace
ASTRAZENECA PLC (AZN) Institutional Holdings & 13F Ownership
ASTRAZENECA PLC offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence. Review AZN institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
- Company
- ASTRAZENECA PLC (AZN)
- Ticker
- AZN
- Market Cap
- $255.1B
- Latest Price
- $164.48
- Industry
- Biotech & Pharma
ASTRAZENECA PLC (AZN) Top Institutional Holders
Top current 13F holders indexed for ASTRAZENECA PLC (AZN). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Ken FisherCIK 0000850529 | $2.1B | 0.73% | Filing2026-05-05 |
| 2 | Sarah KettererCIK 0001165797 | $1.4B | 17.7% | Filing2026-05-14 |
| 3 | Ron BaronCIK 0001017918 | $12.6M | 0.04% | Filing2026-05-15 |
| 4 | Dodge & Cox (advisor level)CIK 0000200217 | $11.3M | 0.01% | Filing2026-05-14 |
| 5 | Polen Capital ManagementCIK 0001034524 | $5.1M | 0.04% | Filing2026-05-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.